Authors

Latest:

Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma

This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.

Matthew Cooperberg, MD

Latest:

Dr. Cooperberg on Using Antagonists for Hormonal Therapy in Prostate Cancer

Matthew Cooperberg, MD, genitourinary cancer specialist, University of California San Francisco, discusses the efficacy of using an antagonist with hormone therapy in prostate cancer.

Matthew D. Galsky, MD

Latest:

Managing Toxicities in Short- and Long-Term Treatment with ADCs

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Matthew D. Hellmann, MD

Latest:

Dr. Hellmann on Tumor Mutational Burden Testing in Patients With Lung Cancer

Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Matthew Davids, MD

Latest:

Dr. Davids Discusses Duvelisib Plus FCR in Young Patients With CLL

Matthew Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, discusses duvelisib plus fludarabine-cyclophosphamide-rituximab (FCR) as a frontline therapy for the treatment of younger patients with chronic lymphocytic leukemia.

Matthew E. Spector, MD

Latest:

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Matthew Farren, PhD

Latest:

Findings for Pembrolizumab Plus mFOLFOX6 in Advanced CRC

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses findings from a multicenter, single-arm phase II clinical trial evaluating the combination of pembrolizumab (Keytruda) and modified leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) in patients with advanced colorectal cancer (CRC).

Matthew Fowler

Latest:

PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

Matthew G. Mei, MD

Latest:

Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphoma

Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell therapies and antibody-drug conjugates (ADCs) in Hodgkin lymphoma.

Matthew Galsky, MD

Latest:

Key Takeaways and Closing Thoughts on ADCs

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Matthew Goetz, MD

Latest:

Dr Goetz on the Early Pharmacokinetic Data With Neoadjuvant (Z)-endoxifen in ER+/HER2– Breast Cancer

Matthew P. Goetz, MD, discusses pharmacokinetic data for neoadjuvant (Z)-endoxifen in estrogen receptor–positive, HER2-negative breast cancer.

Matthew Gubens, MD

Latest:

Dr. Gubens on Prevalence of EGFR/ALK/ROS1 and PD-L1 Expression in NSCLC

Matthew Gubens, MD, an assistant professor of thoracic oncology at the University of California San Francisco, discusses the prevalence of patients with non–small cell lung cancer (NSCLC) who harbor mutations in EGFR/ALK/ROS1 as well as PD-L1 expression.

Matthew H. Katz, MD

Latest:

Radiation Dose Escalation to the Tumor-Arterial Interface of Locally Advanced and Borderline Resectable Pancreatic Cancer

An integrated boost with conventional fractionation to the tumor-arterial interface is unlikely to lead to downstaging in borderline resectable and locally advanced pancreatic cancer.

Matthew H. Kulke, MD

Latest:

Neuroendocrine Tumors: Future Directions in Care

A brief synopsis of future directions in the treatment landscape of advanced neuroendocrine tumors.

Matthew H. Kulke, MD, Dana-Farber Cancer Institute

Latest:

The Nature of Neuroendocrine Tumors

Expert insight on the subtypes of neuroendocrine tumors and current understanding of the disease microenvironment.

Matthew H. Kulke, MD, Harvard Medical School

Matthew H. Kulke, MD, Ochsner Medical Center - Kenner

Matthew H. Taylor, MD, Oregon Health

Latest:

Dr Taylor on Preliminary Efficacy and Safety Data for IO-108 in Advanced Solid Tumors

Matthew H. Taylor, MD, discusses the preliminary data on the use of IO-108 in advanced solid tumors in a phase 1 study.

Matthew H.G. Katz, MD

Latest:

Dr. Matthew Katz on Borderline Resectable Pancreatic Cancer

Matthew H.G. Katz, MD, from the MD Anderson Cancer Center, discusses borderline resectable pancreatic ductal adenocarcinoma, a newer stage of pancreatic cancer introduced by the NCCN in 2003.

Matthew H.G. Katz, MD, FACS

Latest:

Dr. Katz on Neoadjuvant Chemotherapy in Pancreatic Cancer

Matthew H.G. Katz, MD, FACS, discusses the benefit of neoadjuvant chemotherapy in patients with pancreatic cancer.